[Efficacy and tolerability of XXXX as the initial drug used in the treatment of @entity302 ].

@entity1 @entity410 @entity1910 @entity302 @entity2049
@entity2049 is the one of the most prescribed antiepileptic drugs in treatment of partial and generalized @entity410 . Its efficacy in treatment of @entity410 was discovered incidentally during the trials of neuroleptic drugs. Generally it is well tolerated with relatively rare serious side effects. Therapy is introduced gradually, with mean dose between 10-20 mg/kg, and given this way it has the least side effects. Aim of the study was to assess interaction between efficacy, tolerability and overall efficacy of the first prescribed drug, in this case @entity2049 , in the group of @entity1 with partial @entity410 and generalized @entity410 . @entity1 hospitalized at University Pediatric Hospital in Sarajevo with newly diagnosed @entity302 and started therapy with @entity2049 in period from 07.1999 to 07.2002 were investigated. There were 89 @entity1 that fulfilled the criteria. In 29 @entity1 @entity410 remitted after the introduction of therapy (32.58%). After the subsequent correction of therapy further 8 @entity1 were @entity410 free. In total, drug was efficient as a monotherapy in 68 @entity1 (76.40%). Other antiepileptic drugs or polytherapy with @entity2049 were tried in the @entity1 that were not @entity410 free. Adverse effects were reported in 28 @entity1 (31.46%). The most frequent was benign leucopoenia (16 @entity1 , 17.97%) that did not require changes in therapy. @entity1910 was found in 8 @entity1 (8.98%), out of which in 6 therapy had to be stopped. Compliance with therapeutic regime was slightly better with controlled release formulation (89.98%) then with simplex formulation (77.52%), but generally was good. We think that @entity2049 is still the drug of the first choice in treatment of @entity1 with partial @entity302 and generalized @entity410 . It showed good overall efficacy with relatively rare serious side effects.
